These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 20376665)
1. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Daoussis D; Andonopoulos AP Rheumatol Int; 2011 Jun; 31(6):841-2. PubMed ID: 20376665 [TBL] [Abstract][Full Text] [Related]
2. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579 [No Abstract] [Full Text] [Related]
4. Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Nakamura K; Yamashita T; Miura S; Saigusa R; Ichimura Y; Takahashi T; Hirabayashi M; Taniguchi T; Akamata K; Asano Y; Sato S Scand J Rheumatol; 2017 May; 46(3):247-252. PubMed ID: 27900875 [No Abstract] [Full Text] [Related]
5. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O; Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885 [TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Broad K; Pope JE Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098 [TBL] [Abstract][Full Text] [Related]
9. Rituximab and lupus interstitial lung disease: friend or foe? Efthimiou P; Kukar M; Hersh A Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472 [No Abstract] [Full Text] [Related]
10. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Marie I; Dominique S; Janvresse A; Levesque H; Menard JF Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877 [TBL] [Abstract][Full Text] [Related]
11. Is biological therapy in systemic sclerosis the answer? Misra DP; Ahmed S; Agarwal V Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079 [TBL] [Abstract][Full Text] [Related]
12. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Noda S; Akamata K; Miyazaki M; Kuwano Y; Yanaba K; Sato S J Dermatol; 2014 May; 41(5):418-20. PubMed ID: 24801917 [TBL] [Abstract][Full Text] [Related]
13. Rituximab in severe, treatment-refractory interstitial lung disease. Keir GJ; Maher TM; Ming D; Abdullah R; de Lauretis A; Wickremasinghe M; Nicholson AG; Hansell DM; Wells AU; Renzoni EA Respirology; 2014 Apr; 19(3):353-9. PubMed ID: 24286447 [TBL] [Abstract][Full Text] [Related]
14. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770 [TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326 [TBL] [Abstract][Full Text] [Related]
17. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Aringer M; Riemekasten G Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826 [TBL] [Abstract][Full Text] [Related]
18. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Khor CG; Chen XL; Lin TS; Lu CH; Hsieh SC Clin Rheumatol; 2014 Jul; 33(7):1019-20. PubMed ID: 24722688 [TBL] [Abstract][Full Text] [Related]